Aneurysmal Subarachnoid Hemorrhage is a devastating indication with a 90% morbidity and mortality rate, one of the highest amongst diseases. It affects patients primarily in their prime income earning age, between their 40’s and 60’s with lifelong morbidities associate with the survivors. Nimodipine, the standard of care, was approved in 1988 and recent clinical studies have demonstrated questionable clinical efficacy.

ALOX15 ko mice are protected against neuronal damage following SAH and our first-generation inhibitor, stopped the progression of the disease with a 45% reduction in brain injury and a 80% improvement in neurological function.

With the help of a $6M non-dilutive fund we have designed, screened and selected our lead 2nd generation molecule and have shown that we can stop the progression of the disease in two rodent models in a biomarker driven mechanism. Furthermore, we have completed most of the IND enabling studies and are now getting ready to take the molecule to the clinic.